NASDAQ:NVCNNeovasc Stock Price, Forecast & News

Neovasc's stock was trading at $2.21 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVCN stock has increased by 2.7% and is now trading at $2.27.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Neovasc.

Neovasc is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Neovasc.

Neovasc Inc (NASDAQ:NVCN) released its earnings results on Thursday, August, 6th. The medical equipment provider reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.22.
View Neovasc's earnings history.

Neovasc's stock reverse split before market open on Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.

Neovasc issued an update on its second quarter 2020 IntraDay earnings guidance on Monday, July, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $295K - 295K.

3 Wall Street analysts have issued twelve-month price targets for Neovasc's stock. Their forecasts range from $3.00 to $15.00. On average, they expect Neovasc's share price to reach $7.67 in the next twelve months. This suggests a possible upside of 237.7% from the stock's current price.
View analysts' price targets for Neovasc.

Media stories about NVCN stock have trended positive recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neovasc earned a news sentiment score of 2.7 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about Neovasc.

Neovasc saw a decrease in short interest in June. As of June 30th, there was short interest totaling 185,500 shares, a decrease of 13.1% from the June 15th total of 213,500 shares. Based on an average daily trading volume, of 376,800 shares, the short-interest ratio is presently 0.5 days. Approximately 1.4% of the shares of the stock are short sold.
View Neovasc's Short Interest.

Some companies that are related to Neovasc include Venus Concept (VERO), PAVmed (PAVM), BeyondAirInc . (XAIR), Spectral Medical (EDTXF), Neuronetics (STIM), Pro-Dex (PDEX), SANUWAVE Health (SNWV), BRAINSWAY LTD/S (BWAY), Nephros (NEPH), Titan Medical (TMDI), Nephros (NEPHD), AIT Therapeutics (AITB), DarioHealth (DRIO), Sensus Healthcare (SRTS) and Sintx Technologies (SINT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Rexahn Pharmaceuticals (REXN), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Gevo (GEVO), TOP SHIPS (TOPS) and 22nd Century Group (XXII).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Neovasc's stock is owned by many different institutional and retail investors. Top institutional shareholders include Hudson Bay Capital Management LP (5.68%) and Wedbush Securities Inc. (0.40%).

NVCN stock was acquired by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, and Wedbush Securities Inc..

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCN stock can currently be purchased for approximately $2.27.

Neovasc has a market capitalization of $25.27 million and generates $2.09 million in revenue each year. The medical equipment provider earns $-35,130,000.00 in net income (profit) each year or ($5.05) on an earnings per share basis. Neovasc employs 98 workers across the globe.

The official website for Neovasc is www.neovasc.com.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-248-4138 or via email at [email protected]